The European Medicines Agency (EMA) has approved Lecanemab (Leqembi) for use in Europe, a drug aimed at slowing the progression of Alzheimer's disease. Despite this approval, Alzheimer Nederland estimates that fewer than 10% of dementia patients will be eligible for the treatment. Gerjoke Wilmink, director of Alzheimer Nederland, expressed optimism about the approval, calling it "a very important first step in the treatment of dementia."
Limited Applicability
Lecanemab's effectiveness is limited to individuals with Alzheimer's disease, excluding those with other forms of dementia. "People with a form of dementia other than Alzheimer's do not benefit from this drug," Wilmink stated. The treatment is also not suitable for individuals with a genetic predisposition to Alzheimer's or those with cardiovascular diseases.
Mechanism and Impact
Lecanemab works by removing harmful proteins in the brain, which leads to a slower rate of deterioration in the average patient. However, Alzheimer Nederland cautions against raising false hopes, emphasizing the drug's specific limitations and the relatively small patient population for whom it is appropriate.
Call for Expedited Availability
Before Lecanemab can be used in the Netherlands, an extensive procedure is required. Alzheimer Nederland is advocating for a fast-track approach to minimize the period of uncertainty for patients and their families. The organization aims to ensure that eligible patients can access the treatment as quickly as possible.
